deltatrials
Completed PHASE4 NCT00181818

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease

Sponsor: GlaxoSmithKline

Conditions Cardiovascular Disease Myocardial Infarction Smoking Unstable Angina
Interventions bupropion SR (sustained-release)
Updated 4 times since 2017 Last updated: Sep 13, 2005 Started: Oct 31, 1999 Completion: Dec 31, 2003

This PHASE4 trial investigates Cardiovascular Disease and Myocardial Infarction and is currently completed. GlaxoSmithKline leads this study, which shows 4 recorded versions since 1999 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE4

    First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Massachusetts General Hospital
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States